Organon & Co. (OGN) is a Healthcare stock trading at $13.76 (as of 2026-08-21), with a market capitalization of $3.61B and a trailing P/E of 17.3. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Organon & Co. is a healthcare company that develops and provides health solutions through a portfolio of prescription therapies. Its product areas include women’s health, biosimilars, oncology, cardiovascular, respiratory and allergy medicines, dermatology, bone health, and non-opioid pain management, sold in the United States and internationally.
Organon & Co. develops and delivers prescription health solutions, including women’s health therapies (such as Nexplanon/Implanon) and established-brands products (including biosimilars and oncology/cardiovascular medicines), and it makes money by selling these prescription therapies.
The profit engine is the company’s ability to generate steady prescription-sales revenue from differentiated product portfolios, especially its established brands and women’s health therapies.
| Established | $0.9B |
| Women’s Health | $0.5B |
Business quality (Mixed): Clear product portfolio focus (women’s health plus established-brands prescription therapies), but the provided segment detail is not fully comprehensive, so investors should look for more complete segment definitions and sales drivers in official filings.
Valuation: At 14× earnings, OGN trades 15% below the Pharmaceutical Products average (17×). Note: one-time items can distort reported P/E.
| Price | $13.76 |
| Market Cap | $3.61B |
| P/E Ratio | 17.3 |
| EV / EBITDA | 17.0 |
| Price / Book | 3.59 |
| Price / Sales | 0.59 |
| FCF Yield | 15.7% |
| DCF Value (model) | $33.20 |
| DCF Upside vs Price | 141.3% |
| Revenue (TTM) | $6.22B |
| Net Margin | 3.0% |
| Revenue Growth (YoY) | -2.3% |
| EPS Growth (YoY) | -26.8% |
| FCF Growth (YoY) | -64.1% |
| Altman Z-Score | 1.07 (distress) |
| Piotroski F-Score | 5/9 (moderate) |
| Stock P/E | 17.3 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| vs Sector | -20.5% |
| vs Industry | 0.7% |
| Top Institutional Holder | VANGUARD GROUP INC ($264.69M) |
| Institutional Holders Tracked | 10 |
| Congressional Trades (recent) | 3 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | Joseph T. Morrissey Jr. |
| Employees | 10,000 |
| Country | US |
| IPO Date | 2021-05-14 |
Data as of 2026-08-21.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.